Literature DB >> 28197798

Inhibition of proinflammatory pathways by bioactive fraction of Tinospora cordifolia.

Jenny Jacob1, Bashi M Babu1, Mohind C Mohan1, A P Abhimannue1, B Prakash Kumar2.   

Abstract

Tinospora cordifolia (Willd.) Miers ex Hook. f. & Thomson, a known immunomodulatory agent extensively used in ayurveda, has not been effectively validated for the mechanisms involved in immunomodulation and the identification of the active principles. The bioactive fraction of T. cordifolia (TBF) in methanol was used for nitric oxide (NO) radical scavenging activity, lipoxygenase (LOX) and cyclooxygenase (COX) dual inhibition and cytotoxicity studies. Production of the proinflammatory cytokines, tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in dendritic cell (DC) suspensions treated with lipopolysaccharide (LPS) was also studied. The bioactive principles involved were identified with ultra-performance liquid chromatography-quadrupole-time of flight mass spectrometric (UPLC-Q-ToF MS/MS) system. The results indicate significantly higher potency of TBF as compared to positive standards for LOX/COX inhibition with moderate NO radical scavenging activity and the fraction was also found to be non-cytotoxic to monocyte cells. A significant inhibition was also observed in TNF-α and IL-1β production in LPS-treated DC suspensions as compared to standards, rolipram and dexamethasone, respectively. 11 compounds were identified from TBF by MS/MS system. The potent inhibition of LOX and COX enzymes with moderate NO scavenging was indicative of a free radical scavenging-independent mechanism of immunomodulation. Further investigations into the active principles identified would result in the development of lead candidates with potent therapeutic implications.

Entities:  

Keywords:  COX; Cytokines; IL-1β; Immunomodulation; LOX; Medicinal plants; Nitric oxide; TNF-α; Tinospora cordifolia

Mesh:

Substances:

Year:  2017        PMID: 28197798     DOI: 10.1007/s10787-017-0319-2

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  25 in total

Review 1.  Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one?

Authors:  L Parente
Journal:  J Rheumatol       Date:  2001-11       Impact factor: 4.666

Review 2.  Proinflammatory cytokines.

Authors:  C A Dinarello
Journal:  Chest       Date:  2000-08       Impact factor: 9.410

3.  From asthma to atherosclerosis--5-lipoxygenase, leukotrienes, and inflammation.

Authors:  Raffaele De Caterina; Antonella Zampolli
Journal:  N Engl J Med       Date:  2004-01-01       Impact factor: 91.245

4.  The nitric oxide scavenger cobinamide profoundly improves survival in a Drosophila melanogaster model of bacterial sepsis.

Authors:  Kate E Broderick; Jake Feala; Andrew McCulloch; Giovanni Paternostro; Vijay S Sharma; Renate B Pilz; Gerry R Boss
Journal:  FASEB J       Date:  2006-09       Impact factor: 5.191

5.  Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice.

Authors:  B N Lambrecht; B Salomon; D Klatzmann; R A Pauwels
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

6.  Topical anti-inflammatory potential of Physalin E from Physalis angulata on experimental dermatitis in mice.

Authors:  N B Pinto; T C Morais; K M B Carvalho; C R Silva; G M Andrade; G A C Brito; M L Veras; O D L Pessoa; V S Rao; F A Santos
Journal:  Phytomedicine       Date:  2010-02-09       Impact factor: 5.340

7.  The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes.

Authors:  D M Chang; P Baptiste; P H Schur
Journal:  J Rheumatol       Date:  1990-09       Impact factor: 4.666

Review 8.  Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives.

Authors:  M Gordaliza; P A García; J M Miguel del Corral; M A Castro; M A Gómez-Zurita
Journal:  Toxicon       Date:  2004-09-15       Impact factor: 3.033

9.  Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1.

Authors:  Riku Korhonen; Tuija Hömmö; Tiina Keränen; Mirka Laavola; Mari Hämäläinen; Katriina Vuolteenaho; Lauri Lehtimäki; Hannu Kankaanranta; Eeva Moilanen
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

10.  Production of interleukin-1 receptor antagonist by human articular chondrocytes.

Authors:  Gaby Palmer; Pierre-Andre Guerne; Francoise Mezin; Michel Maret; Jerome Guicheux; Mary B Goldring; Cem Gabay
Journal:  Arthritis Res       Date:  2002-04-08
View more
  5 in total

1.  Evaluation of anti-inflammatory effect of Varanadi Kashayam (decoction) in THP-1-derived macrophages.

Authors:  J U Chinchu; Mohind C Mohan; S J Rahitha Devi; B Prakash Kumar
Journal:  Ayu       Date:  2018 Oct-Dec

2.  Modulation of proinflammatory cytokines and enzymes by polyherbal formulation Guggulutiktaka ghritam.

Authors:  Mohind C Mohan; Anu P Abhimannue; B Prakash Kumar
Journal:  J Ayurveda Integr Med       Date:  2019-01-11

3.  Efficacy and safety of Guduchighana Vati in asymptomatic and mild-to-moderate cases of coronavirus disease-19: A randomized controlled pilot study.

Authors:  Umesh Shukla; Nitin Ujjaliya; Pankaj Gupta; Vivek Khare; Babita Yadav; Amit Kumar Rai; Hetalben Amin; Rakesh Rana; Arunabh Tripathi; Shruti Khanduri; Bhagwan Sahay Sharma; Bhogavalli Chandrasekhararao; Narayanam Srikanth; Kartar Singh Dhiman
Journal:  Ayu       Date:  2022-02-24

4.  Anti-inflammatory efficacy of petasin-incorporated zinc oxide eugenol sealer - An in vivo zebrafish study.

Authors:  Selvanathan M J Vinola; Kittappa Karthikeyan; Apoorva Sharma; Sai Sudheshna; Mahalaxmi Sekar
Journal:  J Conserv Dent       Date:  2022-04-01

5.  AYURAKSHA, a prophylactic Ayurvedic immunity boosting kit reducing positivity percentage of IgG COVID-19 among frontline Indian Delhi police personnel: A non-randomized controlled intervention trial.

Authors:  Tanuja Nesari; Sujata Kadam; Mahesh Vyas; Vitthal G Huddar; Pradeep Kumar Prajapati; Manjusha Rajagopala; Anand More; Shri Krishna Rajagopala; Santosh Kumar Bhatted; Rama Kant Yadav; Vyasdeva Mahanta; Sisir Kumar Mandal; Raja Ram Mahto; Divya Kajaria; Rahul Sherkhane; Narayan Bavalatti; Pankaj Kundal; Prasanth Dharmarajan; Meera Bhojani; Bhargav Bhide; Shiva Kumar Harti; Arun Kumar Mahapatra; Umesh Tagade; Galib Ruknuddin; Anandaraman Puthanmadam Venkatramana Sharma; Shalini Rai; Shivani Ghildiyal; Pramod R Yadav; Jonah Sandrepogu; Meena Deogade; Pankaj Pathak; Alka Kapoor; Anil Kumar; Heena Saini; Richa Tripathi
Journal:  Front Public Health       Date:  2022-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.